CAJ | 학술논문

目的：探讨贝伐单抗联合培美曲塞维持治疗晚期非鳞状非小细胞肺癌疗效及对循环microRNA（ miR）-19和白细胞介素（ interleukin，IL）-27表达水平的影响。方法选择2013年3月至2014年3月入住该院的经一线含铂类方案化疗获得控制的晚期非鳞状非小细胞肺癌患者45例，遵循知情同意原则分为培美曲塞组（25例）和贝伐单抗联合培美曲塞组（20例）；分别观察1年内两组疗效以及患者外周血miR-19、IL-27的表达。结果培美曲塞联合贝伐单抗组和培美曲塞组的疾病控制率分别为80％和48％，总有效率分别为45％和24％，两组间疾病控制率和总有效率比较均存在统计学差异（P＜0．05）；培美曲塞联合贝伐单抗组外周血miR-19表达约是培美曲塞组的0．57倍，两组间相比存在统计学差异（P＜0．05）。与培美曲塞组相比，培美曲塞联合贝伐单抗组外周血IL-27表达升高，两组间相比存在统计学差异（P＜0．05）。结论贝伐单抗联合培美曲赛维持治疗有助于改善晚期非鳞状非小细胞肺癌的治疗效果，降低外周血miR-19、升高IL-27的表达。
목적：탐토패벌단항연합배미곡새유지치료만기비린상비소세포폐암료효급대순배microRNA（ miR）-19화백세포개소（ interleukin，IL）-27표체수평적영향。방법선택2013년3월지2014년3월입주해원적경일선함박류방안화료획득공제적만기비린상비소세포폐암환자45례，준순지정동의원칙분위배미곡새조（25례）화패벌단항연합배미곡새조（20례）；분별관찰1년내량조료효이급환자외주혈miR-19、IL-27적표체。결과배미곡새연합패벌단항조화배미곡새조적질병공제솔분별위80％화48％，총유효솔분별위45％화24％，량조간질병공제솔화총유효솔비교균존재통계학차이（P＜0．05）；배미곡새연합패벌단항조외주혈miR-19표체약시배미곡새조적0．57배，량조간상비존재통계학차이（P＜0．05）。여배미곡새조상비，배미곡새연합패벌단항조외주혈IL-27표체승고，량조간상비존재통계학차이（P＜0．05）。결론패벌단항연합배미곡새유지치료유조우개선만기비린상비소세포폐암적치료효과，강저외주혈miR-19、승고IL-27적표체。
Objective To investigate the effect of maintenance therapy with bevacizumab-pemetrexed for advanced non-squamous non-small cell lung cancer and on the levels of circulating microRNA( miR)-19 and interleukin ( IL)-27 expression.Methods 45 patients with advanced no-squamous non-small cell lung cancer and gotten controlled after first-line containing cisplatin chemotherapy who en-rolled into our hospital were randomized into pemetrexed group (n=25) and bevacizumab +pemetrexed group (n=20) accroding to the principle of informed consent.The curative effect of the two groups within 1 year and the expression of circulating miR-19 and IL-27 expression were observed.Results The disease control rate was 80%in bevacizumab +pemetrexed group and was 48%in peme-trexed group,the overall response rate was 45%in bevacizumab +pemetrexed group and was 24%in pemetrexed group.There have significant difference between two groups in the disease control rate and the overall response rate (P<0.05).The levels of circulating miR-19 in bevacizumab +pemetrexed group was 0.57 fold the pemetrexed group.There has significant difference between two groups in the levels of circulating miR-19 (P<0.05).Compared with the pemetrexed group,the levels of circulating IL-27 were increased in bevacizumab +pemetrexed group (P<0.05).Conclusion Maintenance therapy with bevacizumab +pemetrexed for advanced non-squamous non-small cell lung cancer could improve the clinical therapy effect,reduce the levels of circulating miR-19 expression and increased circulating IL-27 expression .